Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort.

• Tác giả: Lutz Achtnichts, Pascal Benkert, Tobias Derfuss, Giulio Disanto, Marcus D'Souza, Renaud Du Pasquier, Maximilian Einsiedler, Sebastian Finkener, Bettina Fischer-Barnicol, Riccardo Galbusera, Claudio Gobbi, Cristina Granziera, Lars G Hemkens, Robert Hoepner, Ludwig Kappos, Jens Kuhle, Patrice Lalive, David Leppert, Johannes Lorscheider, Aleksandra Maleska Maceski, Keltie McDonald, Stefanie Müller, Johanna Oechtering, Caroline Pot, Patrick Roth, Anke Salmen, Sabine Schaedelin, Marjolaine Uginet, Özgür Yaldizli, Chiara Zecca
• Ngôn ngữ: eng
• Ký hiệu phân loại: 639.0916 Hunting, fishing, conservation, related technologies
• Thông tin xuất bản: United States : Multiple sclerosis journal - experimental, translational and clinical , 2025
• Bộ sưu tập: NCBI
• ID: 682607

Tóm tắt

BACKGROUND: Persistence to B cell depleting therapies (BCDT) like ocrelizumab and rituximab may be higher compared with other disease-modifying therapies (DMT) in multiple sclerosis (MS). Clinical trials directly comparing these treatments are lacking. OBJECTIVE: To compare the risk of treatment discontinuation, relapse, and confirmed disability worsening in patients starting BCDT vs other DMT within real-world settings. METHODS: In a longitudinal cohort study, patients with relapsing MS starting BCDT (ocrelizumab/rituximab, RESULTS: Patients starting BCDT were less likely to discontinue treatment than all other DMT combined (HR = 0.26, 95% CI = 0.18-0.36, CONCLUSION: We provide real-world evidence for patients being more persistent to BCDT than to other treatments, and better clinical outcomes may partly explain this.